Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study.
Saved in:
| Title: | Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. |
|---|---|
| Authors: | Sekeres, Mikkael A.1 (AUTHOR) msekeres@med.miami.edu, Santini, Valeria2 (AUTHOR), Díez-Campelo, Maria3 (AUTHOR), Komrokji, Rami S.4 (AUTHOR), Fenaux, Pierre5 (AUTHOR), Savona, Michael R.6 (AUTHOR), Madanat, Yazan F.7 (AUTHOR), Valcárcel-Ferreiras, David8 (AUTHOR), Oliva, Esther Natalie9 (AUTHOR), Regnault, Antoine10 (AUTHOR), Creel, Kristin10 (AUTHOR), Sengupta, Nishan11 (AUTHOR), Dougherty, Souria11 (AUTHOR), Shah, Sheetal11 (AUTHOR), Sun, Libo11 (AUTHOR), Wan, Ying11 (AUTHOR), Navada, Shyamala11 (AUTHOR), Zeidan, Amer M.12 (AUTHOR), Platzbecker, Uwe13 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Mar2025, Vol. 66 Issue 3, p529-534. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
